To include your compound in the COVID-19 Resource Center, submit it here.

Waiting for Zavesca

Even though Actelion Ltd. received U.S. marketing approval for Zavesca on Aug. 1, the company won't launch the product to treat Type I Gaucher's disease in the U.S. until the fourth quarter. Zavesca is already sold in Europe and Actelion has a sales force in place in

Read the full 477 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers